Kura Oncology (KURA) Common Equity (2010 - 2026)

Kura Oncology (KURA) has 17 years of Common Equity data on file, last reported at $107.9 million in Q1 2026.

• Common Equity for Q1 2026 came in at $107.9 million, down 70.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $107.9 million (down 70.39% YoY), and the FY2025 annual result was $174.1 million, down 57.9% from the prior year.
• Common Equity declined to $107.9 million in Q1 2026 per KURA's latest filing, from $174.1 million in the prior quarter.
• Over five years, Common Equity peaked at $505.1 million in Q1 2024 and troughed at $107.9 million in Q1 2026.
• A 5-year average of $379.5 million and a median of $419.6 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2026: Common Equity gained 27.81% in 2024, then plunged 70.39% in 2026.
• A 5-year view of Common Equity shows it stood at $420.3 million in 2022, then declined by 5.47% to $397.3 million in 2023, then climbed by 4.12% to $413.6 million in 2024, then plunged by 57.9% to $174.1 million in 2025, then plunged by 38.05% to $107.9 million in 2026.
• Business Quant data shows KURA's Common Equity at $107.9 million in Q1 2026, $174.1 million in Q4 2025, and $242.5 million in Q3 2025.